Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors

Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors

Mont–Saint–Guibert, Belgium "" January 9, 2023, 10:30pm CET / 4:30pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has appointed Mr. Daniel Wildman as an Independent Director to its Board of Directors*.

Mr. Wildman is a 40–year veteran of the medical device industry. He is currently the Chairman of the Board of Progenerative Medical, Inc. and a Strategic Advisor to several medical device and pharmaceutical companies. He also serves as member of the Board of Directors of UroGen Pharma, Ltd.

Mr. Wildman spent most of his career with Johnson & Johnson ("J&J"), where he led the Digital Surgery Strategy Initiative, J&J's DuPuy Synthes Spine franchise and J&J's Ethicon Biosurgery division. Before J&J, Mr. Wildman spent ten years with Boston Scientific Corporation in a variety of sales, marketing, operations, and strategic planning roles.

Robert Taub, Chairman of the Board of Directors of Nyxoah, commented: "We are delighted to welcome Mr. Wildman to Nyxoah's Board. His wealth of experience and knowledge in the medical device and pharmaceutical industries will be invaluable as Nyxoah expands its R&D, clinical and commercial strategies."

Mr. Wildman added: "I am very impressed by the patient–centric design of Nyxoah's Genio hypoglossal nerve stimulation system and the benefits it can offer those suffering with obstructive sleep apnea. As a member of the Board, I look forward to working with Nyxoah's leadership team to obtain approval and launch Genio in the United States."

* Wildman Ventures LLC, represented by Mr. Daniel Wildman, has been appointed as Director. The appointment is effective immediately, subject to confirmation by the Company's shareholders at the next shareholders' meeting.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio system; future financial performance and market position; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the utility of clinical data in potentially obtaining FDA approval of the Genio system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20–F for the year ended December 31, 2021, filed with the Securities and Exchange Commission ("SEC") on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:
David DeMartino
Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment


GLOBENEWSWIRE (Distribution ID 1000776476)

Biden to Democrats: Nominate Me– Whether You Like It or Not

US President Joseph R. Biden Jr.addresses the general debate of the UN General Assembly’s 76th session. September 2021. Credit: UN Photo/Cia Pak

By Norman Solomon
SAN FRANCISCO, USA, Jan 9 2023 – With 2023 underway, Democrats in office are still dodging the key fact that most of their party’s voters don’t want President Biden to run for re-election. Among prominent Democratic politicians, deference is routine while genuine enthusiasm is sparse.

Many of the endorsements sound rote. Late last month, retiring senator Patrick Leahy of Vermont came up with this gem: “I want him to do whatever he wants. If he does, I’ll support him.”

Joe Biden keeps saying he intends to be the Democratic nominee in 2024. Whether he will be is an open question — and progressives should strive to answer it with a firm No.

The next presidential election will be exceedingly grim if all the Democratic Party can offer as an alternative to the neofascist Republican Party is an incumbent who has so often served corporate power and consistently serves the military-industrial complex.

The Biden administration has taken some significant antitrust steps to limit rampant monopolization. But overall realities are continuing to widen vast economic inequalities that are grist for the spinning mill of pseudo-populist GOP demagogues.

Meanwhile, President Biden rarely conveys a sense of urgency or fervent discontent with present-day social conditions. Instead, he routinely comes off as “status-quo Joe.”

For the future well-being of so many millions of people, and for the electoral prospects of the Democratic Party in 2024, representing the status quo invites cascading disasters. A few months ago, Bernie Sanders summed up this way:

“The most important economic and political issues facing this country are the extraordinary levels of income and wealth inequality, the rapidly growing concentration of ownership, the long-term decline of the American middle class and the evolution of this country into oligarchy.”

Interviewed days ago, Sanders said: “It pains me very, very much that we’re seeing more and more working-class people voting Republican. Politically, that is a disaster, and Democrats have to recognize that serious problem and address it.”

But President Biden doesn’t seem to recognize the serious problem, and he fails to address it.

During the last two years, domestic policy possibilities have been curbed by Biden’s frequent and notable refusals to use the power of the presidency for progress. He did not issue many of the potential executive orders that could have moved the country forward despite Senate logjams.

At the same time, “bully pulpit” advocacy for workers’ rights, voter rights, economic justice, climate action and much more has been muted or nonexistent.

Biden seems unable or unwilling to articulate a social-justice approach to such issues. As for the continuing upward spike in Pentagon largesse while giving human needs short shrift, Biden was full of praise for the record-breaking, beyond-bloated $858 billion military spending bill that he signed in late December.

While corporate media’s reporters and pundits are much more inclined to critique his age than his policies, what makes Biden most problematic for so many voters is his antiquated political approach.

Running for a second term would inevitably cast Biden as a defender of current conditions — in an era when personifying current conditions is a heavy albatross that weighs against electoral success.

A Hart Research poll of registered voters in November found that only 21 percent said the country was “headed in the right direction” while 72 percent said it was “off on the wrong track.”

As the preeminent symbol of the way things are, Biden is all set to be a vulnerable standard-bearer in a country where nearly three-quarters of the electorate say they don’t like the nation’s current path.

But for now’ anyway, no progressive Democrat in Congress is willing to get into major trouble with the Biden White House by saying he shouldn’t run, let alone by indicating a willingness to challenge him in the early 2024 primaries.

Meanwhile, one recent poll after another showed that nearly 60 percent of Democrats don’t want Biden to run again. A New York Times poll last summer found that a stunning 94 percent of Democrats under 30 years old would prefer a different nominee.

Although leaning favorably toward Biden overall, mass-media coverage has occasionally supplied the kind of candor that Democratic officeholders have refused to provide on the record. “The party’s relief over holding the Senate and minimizing House losses in the midterms has gradually given way to collective angst about what it means if Biden runs again,” NBC News reported days before Christmas.

Conformist support from elected Democrats for another Biden campaign reflects a shortage of authentic representation on Capitol Hill. The gap is gaping, for instance, between leaders of the Congressional Progressive Caucus and the constituency — the progressive base — they claim to represent. In late November, CPC chair Pramila Jayapal highlighted the gap when she went out of her way to proclaim that “I believe he should run for another term and finish this agenda we laid out.”

Is such leadership representing progressives to the establishment or the other way around?

Norman Solomon is the national director of RootsAction.org and the executive director of the Institute for Public Accuracy. He is the author of a dozen books including War Made Easy. His next book, War Made Invisible: How America Hides the Human Toll of Its Military Machine, will be published in Spring 2023 by The New Press.

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);